IMGN - ImmunoGen inks deal with Takeda for cancer drug Elahere
2023-08-28 07:12:00 ET
More on ImmunoGen, Takeda, etc.
- ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade)
- ImmunoGen's ELAHERE Has Likely Blockbuster Potential
- ImmunoGen: Comprehensive MIRASOL Data Reinforces Elahere's Potential
- Takeda: Upside Case Strengthening, Looking To 15x Earnings
- ImmunoGen inks licensing deal for antibody-drug conjugates
- ImmunoGen jumps 17% after ASCO readout on Elahere cancer drug
For further details see:
ImmunoGen inks deal with Takeda for cancer drug Elahere